Addressing Barriers in Managing IRAEs Associated with Immune Checkpoint Inhibitor Therapy

Addressing Barriers in Managing IRAEs Associated with Immune Checkpoint Inhibitor Therapy

Addressing Barriers in Managing IRAEs Associated with Immune Checkpoint Inhibitor Therapy

Immune checkpoint inhibitors have revolutionized the treatment of various cancers, but you need to watch out for immune-related adverse events (IRAEs).

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Immune-related adverse events (IRAEs) pose significant hurdles in achieving optimal responses to immune checkpoint inhibitors and represent a clinical challenge for healthcare professionals. Join Drs. Marianne Davies and Julie Brahmer as they discuss the importance of improving clinician awareness and competence in providing timely intervention for IRAEs.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Marianne J. Davies, DNP, ACNP, AOCNP
    Oncology Nurse Practitioner; Associate Professor
    Smilow Cancer Hospital at Yale; Yale University
    New Haven, CT
    No relationships to report 

    Julie R. Brahmer, MD, MSc
    Director, Thoracic Oncology Program and Professor of Oncology
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, MD
    Consulting Fees: Amgen, BMS (uncompensated), Eli Lilly, Genentech/Roche, GlaxoSmithKline, Merck, Regeneron, Sanofi
    Contracted Research: AstraZeneca, BMS, Genentech/Roche, Merck, RAPT Therapeutics, Inc., Revolution Medicines
    Other: Data & Safety Monitoring Board/Committees: GlaxoSmithKline, Sano

    Reviewers/Content Planners/Authors:

    • Marianne J. Davies, DNP, ACNP, AOCNP, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Nick Lombardi has disclosed ownership interest in Vertex Pharmaceuticals.
    • The PIM planners and managers have nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for oncology patients.  After participating in this educational activity, participants should be better able to:

    • Discuss the correlation between immune checkpoint inhibitors (ICIs) and the pathobiology of immune-related adverse events (IRAEs) 
    • Formulate strategies to effectively anticipate, treat, and manage IRAEs with the interprofessional team
  • Target Audience

    This activity is designed to meet the educational needs of physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other members of the interprofessional team who are involved in the management of oncology patients.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Learning Collaborative (GLC) and Postgraduate Institute for Medicine (PIM). GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Joint Accreditation Statement
    ReachMD Healthcare Image

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Prova Education.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for .25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
    (Universal Activity Number - JA4008162-9999-20-2480-H01-P)
    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is .25 contact hours

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    Jointly provided by Postgraduate Institute for Medicine (PIM) and Prova Education.   

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb (BMS).

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC, PIM, and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free